2 Information about rimegepant

Marketing authorisation indication

2.1 Rimegepant (Vydura, Pfizer) is indicated for the 'acute treatment of migraine with or without aura in adults'.

2.2 Rimegepant for preventative treatment is recommended in NICE's technology appraisal guidance on rimegepant for preventing migraine.

Dosage in the marketing authorisation

2.3 The dosage schedule is available in the summary of product characteristics for rimegepant.


2.4 The proposed price of rimegepant is £12.90 per 75 mg tablet (excluding VAT).

  • National Institute for Health and Care Excellence (NICE)